醫藥股普遍下跌 受累A股首掛破底諾誠健華(09969.HK)挫16% 惟永泰生物(06978.HK)急彈19%
醫藥股今天普遍隨大市下跌,尤其是諾誠健華-B(09969.HK)受累於A股首掛破底拖累,最低見8.96元(險守3月中旬所創上市低位8.86元),現報9.09元,急挫16%,一向薄弱勢成交急增至555萬股創半年高。諾誠(688428.SH)於上交所科創板首日掛牌,股價破底,最低見9.01元人民幣,收9.33元人民幣,較發行價11.03元人民幣,下挫15.4%,成交1.13億股。
康龍化成(03759.HK)四連跌,最低見37.7元創近兩年半低,現報38.6元,續跌3.7%。神威藥業(02877.HK)七連跌,最低見4.98元創近兩年低,現報5元,續跌3.8%。威高股份(01066.HK)四連跌兼失守50天線,最低見9.7元,現報9.76元,續跌3%。康希諾(06185.HK)續跌3.6%報47.55元,創近三年低。
然而,永泰生物-B(06978.HK)結束五連跌,股價逆同業重越20天及10天線,最高見4.9元,現報4.03元,急彈19%,成交倍增至1,078萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.